A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: loaded (95), weighed down (29), burdened (63)

Haemochromatosis care pathway

Description
Hereditary Haemochromatosis Care Pathway Aim: Cascade test so that C282Y homozygotes and C282Y/H63D heterozygotes are identified Hereditary haemochromatosis is a
Url
/Media/UHS-website-2019/Docs/Services/Genetics/General-genetics/Haemochromatosis-care-pathway.pdf

AmB-LISOCEL-Cyclophosphamide (300)-Fludarabine (30)

Description
Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY AmB – LISOCEL – CYCLOPHOSPHAMIDE (300) – FLUDARABINE (30) Ambulatory Regimen This regimen is
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-LISOCEL-Cyclophosphamide-300-Fludarabine-30.pdf

AmB-Axicabtagene ciloleucel-Cyclophosphamide (500)-Fludarabine (30)

Description
Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY Large B-cell Lymphoma (LBL) AmB- AXICEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-Axicabtagene-ciloleucel-Cyclophosphamide-500-Fludarabine-30.pdf

AmB - Brexucel - Cyclophosphamide (500) - Fludarabine (30)

Description
Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY Mantle Cell lymphoma (MCL) AmB – BREXUCEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) Ambulatory
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-Brexucel-Cyclophosphamide-500-Fludarabine-30-Ver-1.pdf

InP-Cisplatin-Etoposide-Ifosfamide (VIP)

Description
Chemotherapy Protocol GERM CELL CISPLATIN-ETOPOSIDE-IFOSFAMIDE (VIP) Inpatient Regimen Regimen • Germ Cell – InP-Cisplatin-Etoposide-Ifosfamide (VIP) Indication • Metastatic Germ
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Germcell/InP-Cisplatin-Etoposide-Ifosfamide-VIP.pdf

InP-Cisplatin-Ifosfamide-Paclitaxel (TIP) Ver1.2

Description
Chemotherapy Protocol GERM CELL CISPLATIN-IFOSFAMIDE-PACLITAXEL (TIP) Inpatient Regimen Regimen Germ Cell – InP-Cisplatin-Ifosfamide-Paclitaxel (TIP) Indication Relapsed Metastatic
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Germcell/InP-Cisplatin-Ifosfamide-Paclitaxel-TIP-Ver1.2.pdf

InP methotrexate

Description
Chemotherapy Protocol LYMPHOMA METHOTREXATE Inpatient Regimen Regimen • Lymphoma – InP-Methotrexate Indication • Non-Hodgkin’s Lymphoma (NHL), in particular treatment of primary
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-methotrexate.pdf

HSCTCyclophosphamideTBI_Related_Methotrexate_GvHD

Description
Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT CYCLOPHOSPHAMIDE-TOTAL BODY IRRADIATION (TBI)-METHOTREXATE (GvHD) Related Donor Conditioning This regimen will only be available
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTCyclophosphamideTBI-Related-Methotrexate-GvHD.pdf

HSCTAlemtuzumabCyclophosphamideTBI_VUD_Methotrexate_GvHD

Description
Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT ALEMTUZUMAB-CYCLOPHOSPHAMIDE-TOTAL BODY IRRADIATION (TBI)METHOTREXATE (GvHD) Volunteer Unrelated Donor (VUD) Conditioning This regimen will
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTAlemtuzumabCyclophosphamideTBI-VUD-Methotrexate-GvHD.pdf

InP-MATRix

Description
Chemotherapy Protocol LYMPHOMA MATRix – CYTARABINE-METHOTREXATE-RITUXIMAB-THIOTEPA Inpatient Regimen Regimen • Lymphoma – InP-MATRix – Cytarabine-Methotrexate-Rituximab-Thiotepa Indication • Non-Hodgkin
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-MATRix.pdf
1 to 10 of 38
Previous 1 2 3 4 Next